Search results
Showing 1 to 10 of 10 results for epcoritamab
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
In development Reference number: GID-TA11768 Expected publication date: 03 September 2026
In development Reference number: GID-TA11385 Expected publication date: 25 February 2026
In development Reference number: GID-TA11488 Expected publication date: 15 July 2026
In development Reference number: GID-TA11823 Expected publication date: TBC
Find out what guidance is being considered for development
Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]
Topic prioritisation
In development Reference number: GID-TA11590 Expected publication date: TBC
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.